Tiny doses of avastin tested against laser for preemie eye disease

NCT ID NCT04634604

Terminated Disease control Sponsor: Jaeb Center for Health Research Source: ClinicalTrials.gov ↗

First seen Jun 22, 2026 · Last updated Jun 22, 2026

Summary

This study tested a low dose of the drug bevacizumab (Avastin) against standard laser treatment for retinopathy of prematurity, an eye disease that can blind premature infants. Sixteen babies with severe disease were enrolled. The goal was to see if the drug could control the disease as well as laser, but the trial was stopped early, so the results are not conclusive.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States
Arizonia Pediatric Eye Specialists

Phoenix, Arizona, 85006, United States
Arkansas Childrens Hospital/ University of Arkansas Medical Sciences

Little Rock, Arkansas, 72202, United States
Boston Children's Hospital

Boston, Massachusetts, 02215, United States
CHU - Sainte-Justine

Montreal, Quebec, H3T 1C5, Canada
Casey Eye Institute

Portland, Oregon, 97239, United States
Children's Hospital & Medical Center

Omaha, Nebraska, 68114, United States
Cincinnati Children's Hospital

Cincinnati, Ohio, 45229, United States
Connecticut Childrens Medical Center

Farmington, Connecticut, 06032, United States
Denver Health and Hospital Authority

Denver, Colorado, 80204, United States
Duke University Eye Center

Durham, North Carolina, 27710, United States
Greater Baltimore Medical Center

Baltimore, Maryland, 21204-5809, United States
IWK Health Centre

Halifax, Nova Scotia, B3K 6R8, Canada
Indiana University School of Medicine

Indianapolis, Indiana, 46202, United States
New York Presbyterian David H Koch Center

New York, New York, 10065, United States
Pediatric Ophthalmology Associates, Inc.

Columbus, Ohio, 43205, United States
Riley Hospital for Children

Indianapolis, Indiana, 46202, United States
St. Louis University Ophthalmology

St Louis, Missouri, 63104, United States
Storm Eye Institute

Mt. Pleasant, South Carolina, 29464, United States
Texas Children's Hospital - Dept. Of Ophthalmology

Houston, Texas, 77030, United States
The Emory Eye Center

Atlanta, Georgia, 30322, United States
The Hospital for Sick Children

Toronto, Ontario, M5G 1X8, Canada
The Woman's Hospital of Texas

Houston, Texas, 77054, United States
U of Illinois at Chicago Eye and Ear Infirmary

Chicago, Illinois, 60612, United States
UK Ophthalmology and Visual Sciences, The Eye Clinic

Lexington, Kentucky, 40508, United States
UPMC Children's Eye Center of Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, 15224, United States
Univ of California, Irvine- Gavin Herbert Eye Institute

Irvine, California, 92697, United States
University of California San Francisco Department of Ophthalmology

San Francisco, California, 94143, United States
University of California, Davis

Sacramento, California, 95817, United States
University of Chicago

Hyde Park, Illinois, 60637, United States
University of Colorado Health Sciences Center

Aurora, Colorado, 80045, United States
University of Missouri- Columbia Mason Eye Institute

Columbia, Missouri, 65201, United States
University of North Carolina

Chapel Hill, North Carolina, 27599, United States
University of Utah Moran Eye Center

Salt Lake City, Utah, 84132, United States
Virginia Pediatric Eye Center

Norfolk, Virginia, 23502, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bevacizumab (Avastin)

What this could lead to

If successful, this could offer a less invasive treatment option for retinopathy of prematurity, potentially reducing side effects compared to laser.

What could go wrong

The trial was terminated early with only 16 participants, so results are very limited. It is unclear if low-dose bevacizumab is as effective as laser, and there may be unknown risks.

Conditions

The condition(s) this trial relates to.

Retinopathy of Prematurity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINOPATHY OF PREMATURITY